Clinical Trials Directory
We are doing this study to compare the usual treatment for neuroendocrine carcinomas to using atezolizumab plus the usual treatment. Another purpose is to compare using atezolizumab just at the beginning of treatment to continuing it beyond the initial treatment.
In this study, people will be randomly placed into one of two groups, like flipping a coin. One group will take a new medicine called safusidenib, and the other group will take a fake pill called a placebo. They will take the pills twice a day in 28-day cycles. Doctors will check their health and the size of their brain tumor with regular MRI scans, blood tests, and check-ups. People will also answer questions about how they feel. The study will keep going until the tumor grows or there is another reason to stop.
We are doing this study to collect data and samples to store them for future research. We hope the data and samples will lead to improved treatment of patients who are seriously ill or have been injured.
This is a biosample collection study for people in the Surgical Critical Initiative Tissue and Data Acquisition Study If you join this study, you will: - Have blood drawn (an extra 2 teaspoons) at time of your injury or surgery, on Days 1, 3 and 7 after your injury or surgery, and weekly while you are in the hospital. We may also collect fluid or tissue from your wound and pictures of it We will also collect blood near time of surgery or if you get worse. We will also ask to use data collected under TDAP for analyses.
We are doing this to see the effects of giving long-term red blood cell exchange transfusion to patients with sickle cell disease (SCD). We want to know if exchange blood transfusion may help with serious complications of SCD or reduce the chances of a new, serious problem happening.
We are doing this study to find the most effective, safe dose of an experimental drug called SGR-1505 (the study drug). We want to know how well this study drug specifically targets a protein related to your B-cell cancer.
We are doing this study to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients and their caregivers.
The purpose of this research study is to determine whether data from mobile health technologies (such as smartwatches and smartphones) can be used to assess risk of prediabetes and type 2 diabetes. Using data from smartphones and smartwatches, we may be able to develop a noninvasive procedure for identifying patients who are at risk and should be tested for diabetes. Participants can earn up to $50. For more information about who can be in this study, please contact the study team at diabeteswatch2@duke.edu.